66th ASH Annual Meeting: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies

-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member

denotes an abstract that is clinically relevant.

denotes that this is a recommended PHD Trainee Session.

denotes that this is a ticketed session.

ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies

Special-Interest Sessions

Treatment Considerations

Room 11 (San Diego Convention Center)

Chair:

Cara Rabik, MD, PhD, Food and Drug Administration

Disclosures:

No relevant conflicts of interest to declare.

Cara Rabik, MD, PhD

DHM1/CDER, Food and Drug Administration, Silver Spring, MD

Measurable Residual Disease as an Endpoint in Multiple Myeloma

Maryam Sarraf Sarraf Yazdy, MD

(DHM2/CDER), Food and Drug Administration, Silver Spring

Measurable Residual Disease as an Endpoint in Leukemias

Emily Jen, MD, PhD

US Food and Drug Administration, Silver Spring, MD

Clinical Discussant for MRD

Recent Approvals of CAR T Therapy for Hematologic Malignancies

Lola Fashoyin-Aje

Food and Drug Administration, Silver Spring, MD

Obecabtagene Autoleucel for Treatment of Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Najat Bouchkouj, MD

Division of Clinical Evaluation Hematology, Office of Therapeutic Products (OTP), Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, MD

Clinical Discussant for Acute Lymphoblastic Leukemia

Panel Discussion

Cara Rabik, MD, PhD

DHM1/CDER, Food and Drug Administration, Silver Spring, MD

See more of: Special-Interest Sessions

<< Previous Session | Next Session >>